Stockreport

A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone [Yahoo! Finance]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Arcutis Biotherapeutics (ARQT) has just dosed the first participant in its Phase 1a/1b trial of ARQ-234, a CD200 receptor targeting fusion protein for atopic dermatitis [Read more]